AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00305877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00305877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00258401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
Study NCT00305877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT04248998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Description: Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq
Study NCT00305877 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00305877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00305877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01294475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planned Activities Training
Description: Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
Study NCT00066053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Treatment: SRP
Description: Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
Study NCT00066053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Referral
Study NCT02946346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal sampling
Study NCT03925363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity mobile-application
Description: The active group will be given the feedback app and the control group the blind app
Study NCT03925363 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Physical activity mobile-application
Description: The active group will be given the feedback app and the control group the blind app
Study NCT00776529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor training first, followed by strength exercises
Description: nine sessions of one hour duration
Study NCT00776529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength exercises and sensorimotor exercises alternated
Description: nine sessions of one hour
Study NCT03991910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.
Study NCT03991910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 5Mg Oral Capsule
Description: the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
Study NCT02013375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical Transplant
Description: All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
Study NCT02013375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
Study NCT02013375 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: A 300cGy dose of TBI will be administered in a single fraction on Day -2.
Study NCT02013375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
Study NCT04485845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
Study NCT04485845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril Tablets
Description: used to treat hypertension in metabolic syndrome patients and as a renal protector
Study NCT04485845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril Tablets
Description: used to treat hypertension in metabolic syndrome patients and as a renal protector
Study NCT04485845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
Study NCT01997645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Study NCT01997645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RAF
Study NCT02580877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 67.5 mg oral insulin crystals daily
Description: human insulin crystals in capsules
Study NCT02580877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500mg oral insulin crystals every other week
Description: human insulin crystals in capsules
Study NCT00980148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: FDA approved, a 1 gm single dose, two 500 mg tablets.
Study NCT00980148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: FDA approved, a 100 mg capsule twice a day for 7 days.
Study NCT02973997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02973997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO
Study NCT02973997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: Given PO
Study NCT02973997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02268110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
Study NCT02268110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal binding
Description: Wearing an abdominal binder for 12 weeks
Study NCT00284180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Novel second generation vinca alkaloid
Study NCT00284180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Anti-HER2 monoclonal antibody
Study NCT00041340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00041340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04263844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal dexmedetomidine
Description: subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
Study NCT04263844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Midazolam
Description: subject will receive premedication with intranasal midazolam thirty minutes before induction
Study NCT05140356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applied high amplitude repeated transcranial magnetic stimulation
Description: Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week
Study NCT05140356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applied low amplitude repeated transcranial magnetic stimulation
Description: Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
Study NCT03795649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Imunomodulatory effect
Study NCT03795649 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic Acid
Description: Imunomodulatory effect
Study NCT02013375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
Study NCT00595257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)
Description: autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
Study NCT00595257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)
Description: autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
Study NCT04010097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: The test involves chewing a chewing gum for 4 minutes
Study NCT04010097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: The test involves chewing a chewing gum for 4 minutes
Study NCT02449408 — intervention group
Intervention type: OTHER
Intervention: Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool
Study NCT00987285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASM +
Description: Computer Assisted Self Management plus Social Support
Study NCT00987285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASM
Description: Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
Study NCT02468622 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: There is no intervention, but we will take blood samples during a spontaneous migraine attack
Study NCT02158611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle counseling
Study NCT04218500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Niacinamide 4%
Description: cream moisturizer
Study NCT04218500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virgin Coconut oil 30%
Description: cream moisturizer
Study NCT01708590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered subcutaneous (SC)
Study NCT04610983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Control
Description: 2 x algal oil gel capsules delivering 400mg DHA in total
Study NCT04610983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Treatment 1 - Semi-Solid food matrix
Description: Test Food 1: 200g serve soup + ingredient
Study NCT04610983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2 - Solid food matrix
Description: Test Food 2: 50g serve extruded snack (savoury snack) + ingredient
Study NCT00593060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
Study NCT00593060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
Study NCT02849002 — intervention group
Intervention type: DEVICE
Intervention: BrainPulse
Description: Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
Study NCT00052910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00052910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Given IV
Study NCT00052910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study NCT00158223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide
Description: Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
Study NCT00158223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
Study NCT04588831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthguard
Description: Protective device for orofacial complex for patients playing contact sports
Study NCT00052910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01708590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered subcutaneous (SC)
Study NCT00052910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV
Study NCT00052910 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given 5 days a week for 5 weeks
Study NCT00052910 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 5 weeks
Study NCT01708590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Description: 140 mg brodalumab administered subcutaneous (SC)
Study NCT01708590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered subcutaneous (SC)
Study NCT01708590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered subcutaneous (SC)
Study NCT01593241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
Study NCT01593241 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved node RT
Description: Involved node RT
Study NCT02906241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams
Description: This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
Study NCT02906241 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physicians: Educational Module
Description: Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
Study NCT02135627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
Study NCT00045175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Study NCT00045175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT02135627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current standard therapy
Study NCT03138018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Description: Neuropsychological tests
Study NCT03138018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Description: Neuropsychological tests
Study NCT03138018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Description: Neuroimaging biomarkers of neurodegeneration
Study NCT03138018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Description: Neuroimaging biomarkers of neurodegeneration
Study NCT01757977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double lumen endotracheal tube placement and use
Study NCT01757977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double lumen endotracheal tube placement and use
Study NCT02604810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IGIV-C 10%
Description: IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
Study NCT02604810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20%
Description: IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
Study NCT00442767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.
Study NCT00442767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide + Insulin
Description: 30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
Study NCT02017899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB
Study NCT02827812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive evaluation
Description: At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
Study NCT02827812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive evaluation
Description: At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
Study NCT02827812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Intervention at home
Description: A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
Study NCT02827812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Intervention at home
Description: A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
Study NCT02827812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based telemedicine program
Description: 1. A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~2. A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences.
Study NCT02089932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.